Visit the full analysis for the latest explanation of Vertex Pharmaceuticals Inc.'s stock movement.
Vertex Pharmaceuticals is a large-cap biotech company best known for its dominant franchise in cystic fibrosis treatments, which generated $12 billion in revenue in 2025. The company is actively diversifying into pain management (Journavx), sickle cell disease (Casgevy), and kidney disease (povetacicept). Today's rally was driven by a Q4 revenue beat and management's optimistic commentary on pipeline expansion beyond its core CF business.